PTC Therapeutics CLO Boulding sells 192 shares

The sale's weighted average price was based on multiple trades ranging from $64.00 to $64.70 per share under a written Rule 10b5-1 plan.

Rhea-AI Filing Summary

PTC Therapeutics, Inc. (PTCT) executive vice president and CLO Mark Elliott Boulding exercised options covering 192 shares of common stock at $39.42 per share on October 9, 2026, then sold 192 shares at a weighted average of $64.26 per share. The sale trades ranged from $64.00 to $64.70 per share. Both transactions were effected under a written Rule 10b5-1 plan adopted September 10, 2025. The reported resulting position was 2,267 stock options following the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 192 shares ($5K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Boulding Mark Elliott

Role EXEC. VP AND CLO

Sold 192 shs ($12K)

Approx. gross sale proceeds $12K

Approx. exercise cost $8K

Approx. pre-tax spread $5K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	192	$0.00	$0.00
Exercise	Common Stock F1	192	$39.42	$8K
Sale	Common Stock F1, F2	192	$64.26	$12K

Holdings After Transaction: Stock Option (Right to Buy) — 2,267 contracts (Direct); Common Stock — 105,272 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
2. F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. F3. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Key Figures

Options exercised: 192 shares Exercise price: $39.42 per share Shares sold: 192 shares +2 more

5 metrics

Options exercised 192 shares October 9, 2026

Exercise price $39.42 per share Option exercise on October 9, 2026

Shares sold 192 shares October 9, 2026

Weighted average sale price $64.26 per share Sale trades ranged from $64.00 to $64.70 per share

Stock options following exercise 2,267 options Reported after the October 9, 2026 transaction

Key Terms

Rule 10b5-1 plan, weighted average price, vests over four years

3 terms

Rule 10b5-1 plan regulatory

"written Rule 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"weighted average price of sale transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vests over four years financial

"vests over four years"

A grant that "vests over four years" is a promise that ownership of awarded company shares or options becomes permanent in small portions over a four-year period instead of all at once. Think of it like earning a four-year subscription one month at a time: the recipient gains the right to a bit more stock as time passes, which matters to investors because it affects when employees can sell shares, how quickly ownership shifts, and the timing of potential dilution or insider selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PTCT shares did Mark Elliott Boulding sell, and at what price?

Mark Elliott Boulding sold 192 shares of PTC Therapeutics common stock on October 9, 2026, at a weighted average price of $64.26 per share. The trades ranged from $64.00 to $64.70 per share and were made under a written Rule 10b5-1 plan adopted September 10, 2025.

What was the vesting schedule for Mark Elliott Boulding's option?

The option was granted January 5, 2023, and its terms provide for vesting over four years. 25% of the underlying shares vested on January 5, 2024, followed by an additional 6.25% of the original number of shares at the end of each successive three-month period beginning April 5, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 05:20 PM EDT Accepted by SEC EDGAR 10/13/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boulding Mark Elliott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. VP AND CLO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2026		M(1)		192	A	$39.42	105,464	D
Common Stock	10/09/2026		S(1)		192	D	$64.26(2)	105,272	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$39.42	10/09/2026		M(1)			192	(3)	01/04/2033	Common Stock	192	$0	2,267	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)